Amal Alachkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amal Alachkar has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Michael Brotchie
Atuka Inc., Toronto, Canada
3 shared publications Owen T. Jones
University of Manchester
3 shared publicationsBassam Lajin
2 shared publications- Bassam Lajin
Institute of Chemistry-Analytical Chemistry, NAWI Graz, University of Graz, Universitaetsplatz 1, 8010 Graz, Austria
2 shared publications - Abdul Rezzak Hamzeh
Department of Biochemistry and Microbiology, Faculty of Pharmacy, University of Aleppo, Aleppo, Syria
1 shared publication - Ala-Eddin Al Moustafa
College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
1 shared publication
Latest Publications
- 29 November 2011
- Published by Springer Nature in Breast Cancer
- Vol. 20 (1) , 62-66
Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria
Catechol-O-methyltransferase (COMT) inactivates catechol estrogens by methylation and thus may play a protective role against mutations induced by estrogen metabolites. In this study we investigated the relationship between the Vall58Met polymorphism in the COMT gene and breast cancer risk in a population-based case control study in Syria. We examined 135 breast cancer patients and 107 healthy controls in North Syria to determine the association between the functional genetic Val158Met polymorphism in the COMT gene and female breast cancer risk. There was no significant overall association between the COMT genotype and individual susceptibility to breast cancer. Our data suggest that there may be no overall association between the COMT genotype and breast cancer.
- 29 November 2011
- Published by Springer Nature in Breast Cancer
- Vol. 20 (1) , 62-66
Catechol-O-methyltransferase Val 108/158 Met polymorphism and breast cancer risk: a case control study in Syria
Catechol-O-methyltransferase (COMT) inactivates catechol estrogens by methylation and thus may play a protective role against mutations induced by estrogen metabolites. In this study we investigated the relationship between the Vall58Met polymorphism in the COMT gene and breast cancer risk in a population-based case control study in Syria. We examined 135 breast cancer patients and 107 healthy controls in North Syria to determine the association between the functional genetic Val158Met polymorphism in the COMT gene and female breast cancer risk. There was no significant overall association between the COMT genotype and individual susceptibility to breast cancer. Our data suggest that there may be no overall association between the COMT genotype and breast cancer.
- 12 May 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 46 (1) , 145-152
Changes in the mRNA Levels of α2A and α2C Adrenergic Receptors in Rat Models of Parkinson’s Disease and l-DOPA-Induced Dyskinesia
The changes in the mRNA levels of α2A and α2C adrenoceptors were investigated in unilateral 6-OHDA-lesioned rat model of Parkinson’s disease and l-DOPA-induced dyskinesia using in situ hybridization. In the untreated 6-OHDA-lesioned rats, α2A expression was elevated in the locus coeruleus (160 ± 8% and 142 ± 8% in lesioned and unlesioned sides compared to the comparable side in sham-operated rats). Following long-term (21 days, twice daily) treatment with l-DOPA (25 mg/kg l-DOPA methyl ester plus benserazide 6.25 mg/kg) in 6-OHDA-lesioned rats, levels of α2A adrenoceptor mRNA in the locus coeruleus were decreased, compared to the 6-OHDA-lesioned rats, returning to the levels of α2A mRNA in the sham-operated rats. α2A adrenoceptor expression was not changed in other brain regions in any treatment group. There was no change in α2C expression in the rostral or caudal striatum in which the highest density of α2C mRNA is present. In conclusion, the data presented in this study demonstrate an increase in α2A adrenoceptor mRNA in the locus coeruleus in the 6-OHDA-lesioned rat model of Parkinson’s disease. In addition, the data show that repeated treatment with l-DOPA in 6-OHDA-lesioned rats, which induces dyskinesia, restores α2A mRNA levels. These changes of α2A mRNA expression, observed in the locus coeruleus, might be of importance to basal ganglia transmission and motor function.
- 12 May 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 46 (1) , 145-152
Changes in the mRNA Levels of α2A and α2C Adrenergic Receptors in Rat Models of Parkinson’s Disease and l-DOPA-Induced Dyskinesia
The changes in the mRNA levels of α2A and α2C adrenoceptors were investigated in unilateral 6-OHDA-lesioned rat model of Parkinson’s disease and l-DOPA-induced dyskinesia using in situ hybridization. In the untreated 6-OHDA-lesioned rats, α2A expression was elevated in the locus coeruleus (160 ± 8% and 142 ± 8% in lesioned and unlesioned sides compared to the comparable side in sham-operated rats). Following long-term (21 days, twice daily) treatment with l-DOPA (25 mg/kg l-DOPA methyl ester plus benserazide 6.25 mg/kg) in 6-OHDA-lesioned rats, levels of α2A adrenoceptor mRNA in the locus coeruleus were decreased, compared to the 6-OHDA-lesioned rats, returning to the levels of α2A mRNA in the sham-operated rats. α2A adrenoceptor expression was not changed in other brain regions in any treatment group. There was no change in α2C expression in the rostral or caudal striatum in which the highest density of α2C mRNA is present. In conclusion, the data presented in this study demonstrate an increase in α2A adrenoceptor mRNA in the locus coeruleus in the 6-OHDA-lesioned rat model of Parkinson’s disease. In addition, the data show that repeated treatment with l-DOPA in 6-OHDA-lesioned rats, which induces dyskinesia, restores α2A mRNA levels. These changes of α2A mRNA expression, observed in the locus coeruleus, might be of importance to basal ganglia transmission and motor function.
- 1 July 2010
- Published by Elsevier in Neuroscience Research
- Vol. 67 (3) , 245-249
Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human α2-adrenergic and dopaminergic receptors
- 1 July 2010
- Published by Elsevier in Neuroscience Research
- Vol. 67 (3) , 245-249
Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human α2-adrenergic and dopaminergic receptors